Abstract
Purpose To evaluate the effects of topical citicoline and vitamin B12 (OMK2, Omikron Italia srl, Italy) on the corneal sub-basal plexus density (SBP) of patients with diabetes. Methods This prospective, randomized, double blind, placebo-controlled study included thirty patients with diabetic neuropathy randomised with 2:1 ratio to OMK2 or placebo 3 times daily for 18 months. At baseline and at months 4,8,12,18 patients underwent the Ocular Surface Disease Index questionnaire (OSDI), tear break-up time, evaluation of corneal and conjunctival staining, Schirmer I test, Cochet-Bonnet esthesiometry, and confocal biomicroscopy of SBP. SBP density (mm/mm2) was calculated using NeuronJ. Raw data and differences from baseline were analysed in the two groups. Results 29/30 patients concluded the study. The two groups had similar SBP at baseline; it progressively improved up to month 18 in both groups (OMK2, p<0.0001; controls, <0.0001-0.03); improvement at month 18 vs baseline was higher in OMK2 than placebo (33% vs 15%, p=0.04). A progressive amelioration of corneal sensitivity was also shown just on OMK2 group (baseline, 28±18 mm; month 18, 52±10 mm, p<0.0001). In OMK2 patients, also conjunctival staining and OSDI questionnaire improved during the study (P=0.04 and 0.05). Both treatments were well tolerated and adherence during the study was high. Conclusions OMK2 ameliorated both morphology and function of corneal nerves in patients with diabetes, thus suggesting a neuroprotective effect.